Financial Performance - The company's revenue for Q3 2024 was ¥102,465,558.31, a decrease of 6.27% compared to the same period last year[3] - Net profit attributable to shareholders was ¥17,898,647.03, down 16.27% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥12,067,962.93, reflecting a decline of 31.13% compared to the previous year[3] - Total operating revenue for the current period reached ¥316,018,608.17, a slight increase of 1.4% compared to ¥311,118,638.38 in the previous period[20] - Net profit attributable to shareholders of the parent company was ¥65,578,456.40, down 8.4% from ¥71,412,640.45 in the previous period[21] - The company reported a total profit of ¥78,013,481.54, down 10.4% from ¥87,399,205.58 in the previous period[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥85,301,119.49, down 13.26% year-on-year[3] - Cash inflow from operating activities totaled ¥380,486,083.43, a decrease of 5.6% from ¥403,263,084.54 in the previous period[22] - Cash inflow from investment activities totaled $2,169,906,420.30, significantly up from $457,811,764.07 in the prior period[23] - Cash outflow for investment activities was $2,575,850,909.64, compared to $1,014,015,008.93 previously, resulting in a net cash flow from investment activities of -$405,944,489.34[23] - Cash inflow from financing activities was $13,403,821.84, an increase from $1,000,000.00 in the previous period[23] - Net cash flow from financing activities was -$77,057,966.99, compared to -$69,802,036.68 previously[23] - The total cash and cash equivalents at the end of the period was $167,411,097.53, down from $584,183,219.20 in the prior period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,417,567,072.16, an increase of 1.00% from the end of the previous year[3] - The total liabilities increased to CNY 194,464,746.29 from CNY 147,371,481.33, indicating a rise in financial obligations[18] - The company's equity attributable to shareholders decreased to CNY 2,215,740,460.24 from CNY 2,238,716,685.61, showing a decline in shareholder value[19] - The company's short-term borrowings increased significantly to CNY 16,315,109.46 from CNY 2,200,000.00, reflecting a higher reliance on debt financing[18] Shareholder Information - The company’s total number of ordinary shareholders at the end of the reporting period was 11,735[11] - The largest shareholder, Wan Shiping, holds 25.02% of the shares, totaling 25,063,734 shares[11] - The company reported a total of 32,175,434 restricted shares at the beginning of the period, with 725,000 shares released and 559,125 shares added, resulting in 32,009,559 restricted shares at the end of the period[16] - The largest shareholder, Wan Shiping, holds 25,052,934 restricted shares, which are subject to a lock-up until May 30, 2026[16] - The top 10 shareholders collectively hold a total of 1,064,444 shares, representing 1.06% of the total share capital[14] - The company has a total of 1,492,651 shares in the repurchase special account, accounting for 1.49% of the total share capital at the end of the reporting period[16] Investment and Expenses - The company reported a significant increase in investment income, reaching ¥27,765,340.17, up 843.49% from the previous period's ¥2,942,830.99[9] - Financial expenses decreased to -¥2,760,302.01, a reduction of 68.72% compared to -¥8,824,150.92 in the prior period[9] - The company experienced a 40.19% decrease in taxes paid, totaling ¥34,232,202.96, down from ¥57,234,328.47[10] - Research and development expenses decreased to ¥16,698,408.37, down 17.5% from ¥20,237,381.58 in the previous period[20] - Tax expenses for the current period were ¥12,566,902.08, compared to ¥13,796,860.79 in the previous period, reflecting a decrease of 8.9%[20] Other Information - The company did not undergo an audit for the third quarter report[24] - The report indicates that the company will implement new accounting standards starting in 2024[24]
东星医疗(301290) - 2024 Q3 - 季度财报